CD38 and acute myeloid leukemia: CSCs were first demonstrated in human acute myeloid leukemia (AML) when investigators found that the ability to initiate tumors by transplantation of AML cells into NOD/SCID mice was limited to a CD34+/CD38− subpopulation of leukemic cells (38).